Trevi Therapeutics, Inc. (TRVI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). This report covers the quarterly period ended June 30, 2025. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(12.3) million | $(12.4) million | $(22.6) million | $(23.3) million |
| Operating Expenses | $13.7 million | $13.3 million | $25.2 million | $25.2 million |
| Research & Development | $9.4 million | $10.0 million | $17.2 million | $18.8 million |
| General & Administrative | $4.3 million | $3.3 million | $8.0 million | $6.4 million |
| Cash & Equivalents (Balance) | $117.1 million | $13.0 million | $117.1 million | $13.0 million |
| Marketable Securities (Balance) | $86.8 million | $73.5 million | $86.8 million | $73.5 million |
| Total Liquidity | $203.9 million | $86.5 million | $203.9 million | $86.5 million |
| Accumulated Deficit | $(309.7) million | $(262.4) million | $(309.7) million | $(262.4) million |
Note: The company has no product revenue and has incurred losses since inception. Total liabilities as of June 30, 2025, were $9.8 million.
Material Changes vs. Prior Period
- Capital Raise: In June 2025, the company completed an underwritten public offering (June 2025 Offering) raising approximately $115.1 million in gross proceeds. This significantly increased cash and marketable securities from $34.1 million at year-end 2024 to $203.9 million at June 30, 2025.
- Operating Expenses: Research and development expenses decreased by $1.6 million year-over-year for the six-month period, primarily due to the completion of active enrollment in the Phase 2a RIVER and Phase 2b CORAL trials. General and administrative expenses increased by $1.6 million, driven by higher personnel costs and approximately $0.5 million in costs related to Sarbanes-Oxley (SOX) 404(b) compliance preparation.
- Interest Income: Net interest income increased to $2.5 million for the six months ended June 30, 2025, compared to $1.9 million in the prior year period, reflecting higher invested cash balances.
Guidance, Outlook, and Risks
Clinical Progress & Outlook:
- IPF Program: Announced positive topline results from the Phase 2b CORAL trial in June 2025, showing statistically significant reductions in cough frequency across all dose groups. The company plans to request an End-of-Phase 2 meeting with the FDA in Q4 2025 and initiate a Phase 3 program in H1 2026.
- RCC Program: Announced positive topline data from the Phase 2a RIVER trial in March 2025. The company is designing the next clinical trial for RCC.
- Liquidity Runway: Management believes current resources ($203.9 million) will fund operations into 2029, covering planned Phase 3 trials for IPF, trials for non-IPF ILD, and the next RCC trial. However, additional capital will be required to complete development through regulatory approval and commercialization.
Risks and Contingencies:
- Regulatory Pathway: The company intends to pursue FDA approval under Section 505(b)(2). There is a risk the FDA may require a full New Drug Application (NDA) pathway, increasing costs and timelines.
- Controlled Substance Status: Haduvio contains nalbuphine. While currently unscheduled, there is a risk the DEA could classify it as a controlled substance (Schedule IV or V), which would impose significant regulatory and distribution burdens.
- Third-Party Dependence: The company relies on a single supplier (Mallinckrodt) for the active pharmaceutical ingredient (nalbuphine hydrochloride) and third-party CROs for clinical trials.
- Intellectual Property: The company holds an exclusive license from Endo Pharmaceuticals Inc. Failure to meet diligence obligations could result in loss of license rights.
Investor Verification Checklist
- Capital Efficiency: Verify the specific burn rate and detailed budget assumptions supporting the claim that current cash reserves will fund operations into 2029.
- Phase 3 Design: Confirm the specific design, patient enrollment targets, and estimated costs for the planned Phase 3 IPF program to be initiated in 2026.
- Supply Chain Security: Assess the status of efforts to qualify alternate suppliers for nalbuphine hydrochloride to mitigate single-source risk.
- Regulatory Feedback: Monitor the outcome of the planned End-of-Phase 2 meeting with the FDA in Q4 2025 regarding the 505(b)(2) pathway and Phase 3 requirements.
- Dilution Risk: Review the terms of outstanding warrants (approx. 25 million shares) and the potential impact of future equity financings on shareholder dilution.